Targeted Therapy (Investigational)
44 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (Investigational) (44)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Linrodostat |
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) | Solid Tumour | ||
|
Molecule
Linrodostat
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
||||
Milciclib |
Gamma-Secretase / CDK Inhibitor | Solid Tumour (Sarcoma) | ||
|
Molecule
Milciclib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
||||
Napabucasin |
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) | Solid Tumour | ||
|
Molecule
Napabucasin
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
||||
Navoximod |
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) | Solid Tumour | ||
|
Molecule
Navoximod
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
||||
Nemtabrutinib |
Reversible (Non-Covalent) BTK Inhibitor | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Nemtabrutinib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Reversible (Non-Covalent) BTK Inhibitor |
||||
Nirogacestat |
Gamma-Secretase / CDK Inhibitor | Solid Tumour (Sarcoma) | ||
|
Molecule
Nirogacestat
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
||||
NX-2127 (BTK Degrader) |
Targeted Protein Degrader | Hematologic | ||
|
Molecule
NX-2127 (BTK Degrader)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
||||
NX-5948 (BTK Degrader) |
Targeted Protein Degrader | Hematologic | ||
|
Molecule
NX-5948 (BTK Degrader)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
||||
Pelabresib |
BET Bromodomain Inhibitor | Hematologic (MPN) | ||
|
Molecule
Pelabresib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
BET Bromodomain Inhibitor |
||||
PRN1371 (Investigational FGFR) |
FGFR Inhibitor | Solid Tumour | ||
|
Molecule
PRN1371 (Investigational FGFR)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
||||
Rigosertib |
Polo-Like / Aurora Kinase Inhibitor | Both (Solid & Hematologic) | ||
|
Molecule
Rigosertib
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
||||
Seliciclib (CDK Inhibitor) |
Gamma-Secretase / CDK Inhibitor | Solid Tumour (Sarcoma) | ||
|
Molecule
Seliciclib (CDK Inhibitor)
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
||||
LinrodostatTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
|
MilciclibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
|
NapabucasinTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
|
NavoximodTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
Metabolic Pathway Inhibitor (IDO/STAT3/Glutaminase) |
|
NemtabrutinibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
Reversible (Non-Covalent) BTK Inhibitor |
|
NirogacestatTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
|
NX-2127 (BTK Degrader)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
|
NX-5948 (BTK Degrader)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic
Drug Class / Mechanism
Targeted Protein Degrader |
|
PelabresibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Hematologic (MPN)
Drug Class / Mechanism
BET Bromodomain Inhibitor |
|
PRN1371 (Investigational FGFR)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour
Drug Class / Mechanism
FGFR Inhibitor |
|
RigosertibTargeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Polo-Like / Aurora Kinase Inhibitor |
|
Seliciclib (CDK Inhibitor)Targeted Therapy (Investigational) |
|
|
Therapeutic Category
Targeted Therapy (Investigational)
Oncology Type
Solid Tumour (Sarcoma)
Drug Class / Mechanism
Gamma-Secretase / CDK Inhibitor |
|